{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:57:17Z","timestamp":1792785437336,"version":"4.5.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Japan College of Rheumatolog"},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H30-menneki-shitei-002"],"award-info":[{"award-number":["H30-menneki-shitei-002"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japan College of Rheumatolog"},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["H30-menneki-shitei-002"],"award-info":[{"award-number":["H30-menneki-shitei-002"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the risk factors and clinical characteristics of lymphoproliferative disorder (LPD) in Japanese patients with rheumatoid arthritis (RA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We enrolled patients with RA aged \u226520 years who visited the participating hospitals between April 2011 and July 2011. We investigated the risk factors for LPD using a Cox proportional hazard model and described pathological features and vital prognosis of LPD in patients with RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We enrolled 9815 patients with the following characteristics at baseline: female 79.4%, median age 63 years; median disease duration 7 years; median DAS28-CRP (3) 3.1; prevalence of MTX use 60.0%. Sixty-eight patients (0.69%) developed LPD in 3-year observation period. Multivariable analysis showed that age by decade (hazard ratio [95% confidence interval], 1.47 [1.18\u20131.85]) and MTX use at baseline (2.35 [1.25\u20134.42] for \u22648\u2009mg\/week, 4.39 [2.07\u20139.32] for &amp;gt;8\u2009mg\/week versus non-use) were significant risk factors of LPD. Of 55 patients with pathological diagnosis, diffuse large B cell lymphoma was the most frequent (54%). The 5-year mortality of LPD was 24%. The major cause of death was lymphoma (81%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This nationwide study revealed risk factors, clinical characteristics, and prognosis of LPD in the largest number of Japanese patients with RA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1080\/14397595.2020.1869370","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T03:19:55Z","timestamp":1610594395000},"page":"16-23","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":38,"title":["Association of methotrexate use and lymphoproliferative disorder in patients with rheumatoid arthritis: Results from a Japanese multi-institutional retrospective study"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4846-3234","authenticated-orcid":false,"given":"Suguru","family":"Honda","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Tokyo Women\u2019s Medical University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1640-1373","authenticated-orcid":false,"given":"Ryoko","family":"Sakai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tokyo Women\u2019s Medical University School of Medicine, Tokyo, Japan"},{"name":"Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Department of Rheumatology, Tokyo Women\u2019s Medical University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Inoue","sequence":"additional","affiliation":[{"name":"Showa University Research Administration Center, Showa University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masako","family":"Majima","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tokyo Women\u2019s Medical University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Konda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tokyo Women\u2019s Medical University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Takada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tokyo Women\u2019s Medical University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Kihara","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yajima","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan"},{"name":"Center for Innovative Research for Communities and Clinical Excellence, Fukushima Medical University, Fukushima, Japan"},{"name":"Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Nanki","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Riken Center for Integrative Medical Sciences, Saitama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, School of Medicine, Keio University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Harigai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tokyo Women\u2019s Medical University School of Medicine, Tokyo, Japan"},{"name":"Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Department of Rheumatology, Tokyo Women\u2019s Medical University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"key":"2022010903465845300_R1","author":"World Health Organization."},{"key":"2022010903465845300_R2","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"issue":"3","key":"2022010903465845300_R3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/1097-0215(20001101)88:3<497::AID-IJC27>3.0.CO;2-J","article-title":"Risk of malignancy among patients with rheumatic conditions","volume":"88","author":"Thomas","year":"2000","journal-title":"Int J Cancer"},{"issue":"2","key":"2022010903465845300_R4","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1186\/ar2404","article-title":"A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis","volume":"10","author":"Smitten","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2022010903465845300_R5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2017.1352477","article-title":"Lymphoproliferative disorders in patients with rheumatoid arthritis in the era of widespread use of methotrexate: a review of the literature and current perspective","volume":"28","author":"Harigai","year":"2018","journal-title":"Mod Rheumatol"},{"issue":"4","key":"2022010903465845300_R6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3899\/jrheum.140533","article-title":"Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population","volume":"42","author":"Hashimoto","year":"2015","journal-title":"J Rheumatol"},{"issue":"5","key":"2022010903465845300_R7","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3109\/14397595.2016.1141740","article-title":"Risk for malignancy in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs compared to the general population: a nationwide cohort study in Japan","volume":"26","author":"Harigai","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"11","key":"2022010903465845300_R8","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1007\/s00296-017-3811-5","article-title":"Incidence of comprehensive hospitalization due to infection, cardiovascular disease, fractures, and malignancies in patients with rheumatoid arthritis","volume":"37","author":"Sugimoto","year":"2017","journal-title":"Rheumatol Int"},{"issue":"11","key":"2022010903465845300_R9","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s00296-010-1524-0","article-title":"Incidence of malignancy in Japanese patients with rheumatoid arthritis","volume":"31","author":"Yamada","year":"2011","journal-title":"Rheumatol Int"},{"key":"2022010903465845300_R10","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","article-title":"Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis","volume":"17","author":"Simon","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"2022010903465845300_R11","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/art.40017","article-title":"Rheumatoid arthritis and risk of malignant lymphoma: is the risk still increased?","volume":"69","author":"Hellgren","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"2022010903465845300_R12","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood.V99.11.3909","article-title":"Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France","volume":"99","author":"Mariette","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2022010903465845300_R13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/art.21675","article-title":"Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis","volume":"54","author":"Baecklund","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2022010903465845300_R14","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s10067-017-3634-5","article-title":"Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort","volume":"36","author":"Shimizu","year":"2017","journal-title":"Clin Rheumatol"},{"issue":"2","key":"2022010903465845300_R15","first-page":"322","article-title":"Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication","volume":"34","author":"Hoshida","year":"2007","journal-title":"J Rheumatol"},{"issue":"1","key":"2022010903465845300_R16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ejh.12116","article-title":"Methotrexate\/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression","volume":"91","author":"Ichikawa","year":"2013","journal-title":"Eur J Haematol"},{"issue":"4","key":"2022010903465845300_R17","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1080\/14397595.2017.1387223","article-title":"Polymorphic lymphoproliferative disorders in patients with rheumatoid arthritis are associated with a better clinical outcome","volume":"28","author":"Tsukui","year":"2018","journal-title":"Mod Rheumatol"},{"key":"2022010903465845300_R18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jbi.2017.05.003","article-title":"A pragmatic method for transforming clinical research data from the research electronic data capture \u201cREDCap\u201d to Clinical Data Interchange Standards Consortium (CDISC) Study Data Tabulation Model (SDTM): development and evaluation of REDCap2SDTM","volume":"70","author":"Yamamoto","year":"2017","journal-title":"J Biomed Inform"},{"issue":"7","key":"2022010903465845300_R19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41393-018-0169-9","article-title":"REDCap: web-based software for all types of data storage and collection","volume":"56","author":"Harvey","year":"2018","journal-title":"Spinal Cord"},{"key":"2022010903465845300_R20","author":"About REDCap"},{"issue":"15","key":"2022010903465845300_R21","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1002\/sim.3618","article-title":"Imputing missing covariate values for the Cox model","volume":"28","author":"White","year":"2009","journal-title":"Stat Med"},{"key":"2022010903465845300_R22","first-page":"75","article-title":"Multiple imputation for nonresponse in surveys","author":"Rubin","year":"1987"},{"issue":"5","key":"2022010903465845300_R23","doi-asserted-by":"crossref","first-page":"763","DOI":"10.3109\/14397595.2013.878016","article-title":"Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis","volume":"24","author":"Yoshida","year":"2014","journal-title":"Mod Rheumatol"},{"issue":"9","key":"2022010903465845300_R24","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/acr.22306","article-title":"Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients","volume":"66","author":"Kameda","year":"2014","journal-title":"Arthritis Care Res"},{"issue":"2","key":"2022010903465845300_R25","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3899\/jrheum.130270","article-title":"A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders","volume":"41","author":"Yamakawa","year":"2014","journal-title":"J Rheumatol"},{"issue":"6","key":"2022010903465845300_R26","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s10552-009-9298-y","article-title":"Risk of cancer among rheumatoid arthritis patients in California","volume":"20","author":"Parikh-Patel","year":"2009","journal-title":"Cancer Causes Control"},{"issue":"5","key":"2022010903465845300_R27","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/ard.2005.044784","article-title":"Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritis","volume":"65","author":"Franklin","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2022010903465845300_R28","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/ard.2007.085852","article-title":"Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register","volume":"68","author":"Askling","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2022010903465845300_R29","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/art.22579","article-title":"The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation","volume":"56","author":"Wolfe","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2022010903465845300_R30","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"19","key":"2022010903465845300_R31","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"issue":"5","key":"2022010903465845300_R32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/ar2026","article-title":"Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et\u00a0al","volume":"8","author":"Dixon","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"2022010903465845300_R33","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","article-title":"Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"2022010903465845300_R34","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMcp1702514","article-title":"Primary Sj\u00f6gren\u2019s syndrome","volume":"378","author":"Mariette","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2022010903465845300_R35","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Roy Stat Soc B"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1080\/14397595.2020.1869370\/41812087\/1869370.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/1\/16\/42083528\/1869370.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/32\/1\/16\/42083528\/1869370.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T06:22:12Z","timestamp":1724307732000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/32\/1\/16-23\/6468898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,3,1]]},"published-print":{"date-parts":[[2022,1,5]]}},"URL":"https:\/\/doi.org\/10.1080\/14397595.2020.1869370","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2021,3,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=imor20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=imor20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-09-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}